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A B S T R A C T   
Recently the use of microRNAs (miRNAs) as biomarkers for a multitude of diseases has gained substantial sig-
nificance for clinical as well as point-of-care diagnostics. Amongst other challenges, however, it holds the central 
requirement that the concentration of a given miRNA must be evaluated within the context of other factors in 
order to unambiguously diagnose one specific disease. In terms of the development of diagnostic methods and 
devices, this implies an inevitable demand for multiplexing in order to be able to gauge the abundance of several 
components of interest in a patient’s sample in parallel. In this study, we design and implement different mul-
tiplexed versions of our electrochemical microfluidic biosensor by dividing its channel into subsections, creating 
four novel chip designs for the amplification-free and simultaneous quantification of up to eight miRNAs on the 
CRISPR-Biosensor X (‘X’ highlighting the multiplexing aspect of the device). We then use a one-step model assay 
followed by amperometric readout in combination with a 2-min-stop-flow-protocol to explore the fluidic and 
mechanical characteristics and limitations of the different versions of the device. The sensor showing the best 
performance, is subsequently used for the Cas13a-powered proof-of-concept measurement of two miRNAs 
(miRNA-19b and miRNA-20a) from the miRNA-17–92 cluster, which is dysregulated in the blood of pediatric 
medulloblastoma patients. Quantification of the latter, alongside simultaneous negative control measurements 
are accomplished on the same device. We thereby confirm the applicability of our platform to the challenge of 
amplification-free, parallel detection of multiple nucleic acids.   
1. Introduction 
An increasing number of studies have documented the emergence of 
dysregulated, circulating microRNAs (miRNAs) as biomarkers for 
various diseases such as cancer (Palanichamy and Rao, 2014), Hun-
tington’s disease (Johnson et al., 2008) and psychiatric diseases (Miller 
and Wahlestedt, 2010). These short (18–25 nucleotides) non-coding 
oligonucleotides are involved in the regulation of a wide range of 
physiological processes through degradation or translational repression 
of their target messenger RNAs (mRNAs) (Bartel, 2009) and may also 
impact their structure and interaction with proteins (Filipowicz et al., 
2008). Therefore, dysregulation of miRNAs, and hence aberrant abun-
dance in human body fluids, (blood, saliva or cerebrospinal fluid (Chen 
et al., 2008; Handy et al., 2011; Perdaens et al., 2020)), is being inves-
tigated as a novel, non- or minimally invasive diagnostic biomarker 
(Cheng, 2015). 
However, to this date, it is impossible to accurately and unambigu-
ously diagnose a particular illness by merely assessing the incidence of 
one specific dysregulated ‘signature’ miRNA within a clinical sample. 
Also, there is no commonly accepted standard for the interpretation of 
miRNAs as biomarkers. This is partially due to the fact that each miRNA 
is estimated to target hundreds of transcripts (Friedman and Jones, 
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2009) with implications in cell proliferation, development and differ-
entiation (Gregory and Shiekhattar, 2005), rendering their downstream 
characterization highly complex. A way to circumvent this problem is 
the quantification of not only one but multiple members of a signature 
cluster of up- or downregulated miRNAs (Xie et al., 2011). In our pre-
vious work (Bruch et al., 2019), we combined an electrochemical 
microfluidic biosensing approach with a clustered regularly interspaced 
short palindromic repeats (CRISPR)-powered assay, for target 
amplification-free detection of nucleic acids. 
In this study, we employ the Leptotrichia wadei Cas13a (Shmakov 
et al., 2017) for the simultaneous detection and quantitative analysis of 
different miRNAs of interest. The effector’s nuclease activity depends on 
guidance by a CRISPR-RNA (crRNA) targeting an RNA sequence of in-
terest, upon the recognition of which it collaterally cleaves the single 
stranded reporter RNAs (reRNAs), provided in its immediate vicinity 
(Abudayyeh et al., 2016). 
Like Chin and colleagues, we create a microfluidic multiplexed lab- 
on-a-chip (LOC) device by spatially separating multiple immobiliza-
tion areas within a single channel (Chin et al., 2011), to implement a 
miniaturized system for highly sensitive electrochemical detection of 
miRNAs. This approach is faster, cheaper, easier to handle and more 
economic in terms of sample and reagent consumption (Whitesides, 
2006; Yager et al., 2006), compared to the current gold standard for 
miRNA analysis, which is reverse transcriptase quantitative polymerase 
chain reaction (RT-qPCR). Another advantage of the method presented 
here is that it directly provides absolute values, detected in the patient’s 
sample, in contrast to an x-fold in- or decrease in the abundance of the 
target miRNA detected by RT-qPCR. In our recent work, we presented 
the first CRISPR/Cas13a-powered electrochemical microfluidic 
biosensor for on-site miRNA detection, without the need for target 
amplification (Bruch et al., 2019). Assay calibration revealed the 
limit-of-detection (LOD) to reside within the low pM-range (2–18 pM, 
depending on cleavage-time), which makes it applicable to the analysis 
of real patient’s serum samples. In addition, we were able to defy the 
common conception that signal-off approaches are generally less sensi-
tive than signal-on methods, by showing that the detection limit of our 
CRISPR-powered assay surpassed the sandwich (signal-on) assay’s LOD 
(1.28 nM) by a factor 1000 (Kutluk et al., 2020). To validate its per-
formance, we compared the results obtained by the CRISPR-powered 
biosensor to RT-qPCR measurements of the same samples. Here, we 
introduce the CRISPR-Biosensor X for the simultaneous quantification of 
multiple miRNAs from a single specimen by combining the 
single-channel design with a microfluidic stop-flow protocol. 
2. Material and methods 
2.1. Electrochemical microfluidic multiplexed biosensor 
The microfluidic biosensor chip, manufactured based on dry-film 
photoresist technology according to (Bruch et al., 2017) (see Support-
ing Material for more information), is divided into two functional units: 
the incubation area (the microfluidic channel onto the surface of which 
relevant assay components are immobilized) and the electrochemical 
cell, consisting of a working electrode (platinum, Pt), a reference elec-
trode (silver/silver chloride, Ag/AgCl) and a counter electrode (Pt), for 
the amperometric readout. The former spans the following dimensions: 
40 or 20 mm in length, respectively, 0.5 mm in width and 64 μm in 
height. These parameters were optimized by simulations (see Support-
ing Information) as well as real implementations and are a trade-off 
between microfluidic dynamics, capacity of biomolecule adsorption 
and limitations in fabrication (see Chapter 3). By approaching the 
multiplexing challenge with a single-channel solution (one channel, 
housing several sequential incubation areas), as shown in Fig. 1, we 
reduce the number of working electrodes, and thus the required 
potentiostat channels, to one per channel section in four different de-
signs (Dincer et al., 2019). Formats employed in this study are listed in 
Table 1. 
In comparison with the parallel channel design employed in our 
previous work (Kling et al., 2016), the use of a serial design provides 
superior fluidic control due to a consistent flow rate (which is crucial for 
flow rate-dependent current signals) and a lower possibility of air bub-
bles being trapped within the channel. Furthermore, it fits onto an 
overall smaller layout (19.5 × 28.3 mm) than its predecessor (35.5 ×
27.5 mm). These adjustments increase the fabrication density and 
functional efficiency and hence lower the price per chip (see Supporting 
Information). 
2.2. CRISPR-powered miRNA assay 
The concept of our assay builds on the target-recognition induced 
collateral nuclease activity of the Cas13a/crRNA-complex (see Sup-
porting Video). For its formation, the effector nuclease (preparation 
according to (Bruch et al., 2019), its target-complementary crRNA (or-
dered as DNA and reversed, Biomers, Germany) and a murine RNase 
inhibitor (M0314L, New England BioLabs, Germany) are incubated in 
Tris-buffer (MgCl2 (6 mM), Tris (40 mM), NaCl (60 mM); pH 7.3) for 15 
min at 37 ◦C. The reRNA (Reporter_RNA_14b_2′OMe-A, Biomers, Ger-
many), labelled with biotin and 6-FAM on the 3′ and 5′-end, respec-
tively, as well as the targets: miR-19b or miR-20a (Biomers GmbH, 
Germany), are added for a 3-h incubation at the same temperature. Upon 
Fig. 1. (A) Illustration of the single-channel multiplexing approach. The top 
part shows one channel section (green) with two incubation areas (black), 
separated by a spacer. At the end of each section, an electrochemical cell (grey) 
performs the amperometric signal readout. To automatically meter the capillary 
filling of the incubation areas, hydrophobic stopping barriers (blue) are placed 
between each spacer and incubation area, as well as in front of and behind the 
electrochemical cell. The lower part displays the entire channel subdivided into 
four channel sections (SB: stopping barriers, WE: working electrode, RE: 
reference electrode, CE: counter electrode). (B) - (E) The implemented multi-
plexed sensor designs: 2xN2, 2x2xN2, 4xN2 and 4xN1 sensors. (For interpre-
tation of the references to colour in this figure legend, the reader is referred to 
the Web version of this article.) 
Table 1 
Summary of the key numbers of all multiplexed sensor designs employed in this 
study. The lengths of the different channel subsections are given in mm (IA: 
immobilization area, CS: channel section (N), EC: electrochemical cell).   
1st IA (mm) 2nd IA (mm) Spacer (mm) # CSs # ECs 
2xN2 40 20 35 2 2 
2x2xN2 40 20 34 4 4 
4xN2 40 20 34 4 4 
4xN1 22 – – 4 4  
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target recognition, the effector is activated and cleaves the reporter RNA 
(Fig. 2). For information on oligonucleotides used in this study please 
refer to Supporting Information. Furthermore, the interested reader is 
referred to (Bruch et al., 2019) for more information on assay design and 
development as well as the optimization of reagent concentrations, 
blocking strategy and design of the reRNA and crRNA. 
Supplementary video related to this article can be found at htt 
ps://doi.org/10.1016/j.bios.2020.112887 
In the first step, the surfaces of the different immobilization areas are 
pre-functionalized with streptavidin (0.8 mg ml-1 in PBS (10 mM; pH 
7.4); S4762-.5 MG, Merck, Germany). Prior to the introduction of the 
test-solution, the surfaces are blocked with bovine serum albumin (1% 
in PBS (10 mM, pH 7.4); 126,609-5 GM, ThermoFischer Scientific, USA) 
to prevent unspecific binding of reagents. This blocking step is necessary 
since the functionalization of the microchannel is based on physical 
adsorption of biomolecules to the epoxy-based, negative photoresist (i. 
e., SU-8) layer of the sensor. Subsequently, the different sample solu-
tions are applied in the respective immobilization areas and in the final 
incubation step, a glucose oxidase (GOx)-conjugated (for a detailed 
description of the antibody conjugation see Supporting Information) 
monoclonal anti-6-FAM antibody (SAB4600050-125UL, Merck, Ger-
many) is introduced. Since the antibody will only bind to the reporter’s 
6-FAM label, reRNAs cleaved by Cas13a will not contribute to the cur-
rent signal. Hence, the signal obtained from the enzymatic readout re-
flects the amount of immobilized GOx and is therefore, inversely 
proportional to the target concentration in the sample. 
The application of bioreagents to the microchannel is conducted and 
regulated by capillary forces. Thus, propagation of the fluid, applied to 
the channel inlet, will stop once it reaches a hydrophobic stopping 
barrier. All incubation steps are followed by a washing step: adding 
wash buffer (PBS with 0.05% Tween, pH 7.4, P3563, Merck, Germany) 
into the outlet and applying the vacuum to the inlet of the channel, we 
remove all unbound biomolecules from the microfluidic channel 
without contaminating the electrochemical cell. The total processing 
time required to analyze one patient’s sample with the proposed plat-
form amounts to approximately three and a half hours, including about 
20 min of hands-on time. 
2.3. Electrochemical signal readout 
For the electrochemical signal readout, the sensor is placed into a 
custom-made chip-holder on a printed circuit board (PCB, Beta LAYOUT 
GmbH, Germany). The inlet and outlet of the microchannel are con-
nected to a syringe pump (PHD 2000; Harvard Apparatus, USA) via 
silicone (inlet line) and Teflon (outlet line) tubes, respectively. Prior to 
the measurement, the working electrodes are pre-conditioned to remove 
manufacturing residues from their surfaces. In this process, the elec-
trode’s potential is cycled (5 s at each 0.8 and − 0.05 V vs. the on-chip 
reference electrode) 30 times, while PBS (10 mM, pH 7.4) is passed 
through the channel and over the electrochemical cell at a flow rate of 
20 μl min-1. 
In order to perform the amperometic measurement (0.45 V vs. the 
on-chip reference electrode), a glucose solution (40 mM in PBS (10 mM; 
pH 7.4); Merck, Germany) is introduced to the microfluidic channel. To 
amplify the signal peaks, we apply a stop-flow-protocol during which all 
incubation areas are first filled with the substrate followed by a delay of 
the flow (5 μl min-1) for 2 min. This allows the enzyme (GOx) to convert 
the glucose substrate into the electrochemically active hydrogen 
peroxide, which accumulates within the different incubation areas and, 
upon restart of the flow, gets oxidized at the respective working elec-
trode. The working electrode is part of the electrochemical cell, which is 
connected via the PCB to a four-channel potentiostat (MultiEmStat3; 
PalmSens, The Netherlands). The digital readout of the amperometric 
signal (Dincer et al., 2016) as well as the pre-conditioning of the working 
electrodes are performed with the corresponding software (Multitrace 
4.3.; PalmSens, The Netherlands). 
3. Theory 
To approximate the ideal design parameters for the fabrication of a 
functional single-channel multianalyte biosensor, we developed a 3D 
geometry (Fig. S1) using the finite element method (COMSOL Multi-
physics® 5.3; COMSOL Inc., Sweden) including all essential elements 
(inlet, outlet, channel width, height and curvature, stopping barriers and 
area of the working electrode) for the simulation of its microfluidic 
characteristics. Their respective parameters (Table S1) were hereby kept 
as close to the actual manufacturing ones as possible. We assume this 
method to result in a highly realistic prognosis of the chip performance 
and only very small divergence from the real measurements (Fig. S3) 
(Bruch, 2020; Dincer, 2016). 
For the simulation of the microfluidic dynamics, we used the 
creeping flow model. The boundary conditions of all channel-walls, 
other than the SU-8 surface of the immobilization area, were defined 
as “no flow”. The time-dependent, enzyme-based generation of elec-
troactive species (i.e., the conversion of glucose to hydrogen peroxide 
catalyzed by GOx) flux boundary condition settings are applied to the 
“Transport of diluted species” model. This transport along the channel is 
modeled with forced convection to reflect the syringe pump, used in the 
experimental setup. The simulations were solved on a Windows 10 En-
terprise 64-bit platform using an Intel® Core™ i3-5005U processor at 2 
GHz with 8 GB RAM. 
To investigate possible influences of channel height and flow speed 
on the microfluidic dynamics, variations of both parameters were 
simulated (Fig. S3 and Fig. S4). As a result of these simulations, as well 
as considering fabrication and material limitations, a channel height of 
64 μm and flow speeds between 5 and 10 μl min-1 were selected as the 
most suitable combination for stable and reproducible real measure-
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Fig. 2. CRISPR-powered miRNA targeting. In the absence of a target the 
Cas13a/crRNA complex does not cleave the biotin and 6-FAM labelled reRNA 
bound to SA on the channel surface, allowing the GOx-conjugated anti-6-FAM- 
antibody to bind to the 6-FAM label on the reporter and thus enabling enzy-
matic readout, i.e., the conversion of glucose to hydrogen peroxide (left). In the 
presence of the target, the reporter is cleaved and no enzymatic labeling takes 
place (right). The channel surface was coated with SA for reporter binding 
followed by BSA to prevent unspecific adsorption of biomolecules. (BSA: Bovine 
Serum Albumin, GOx: Glucose Oxidase, SA: Streptavidin, reRNA: reporter RNA, 
crRNA: CRISPR RNA, 6-FAM: 6-carboxyfluorescein). 
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length: On the one hand, it needs to be long enough to guarantee suf-
ficient separation of the successive signals, while on the other hand, it 
has to be as short as possible to not reduce the peak height of the second 
signal’s peak due to dispersion of the electroactive species (see section 
Design Rules and Considerations in Supporting Information). Simulation 
of different spacer lengths (20, 25, 33 and 41 mm) revealed 33 mm as 
the optimum (Fig. S5). Since alteration of the spacer length was not 
sufficient, we chose to also extend the length of the first immobilization 
area. Keeping the overall channel length constant, we shifted the ratio 
(first immobilization area:spacer) to 1.5 and the ratio (first immobili-
zation area:second immobilization area) to 2. These alterations resulted 
in a clear separation, with the signal reaching the baseline level, be-
tween the two identically high peaks, as displayed in Fig. S6. 
4. Results and discussion 
4.1. The 2xN2 sensor 
In order to implement the concept of multiple, spatially separated 
incubation areas within one microfluidic channel, the 2xN2 sensor chip 
(Fig. 3A) was designed and manufactured based on parameters opti-
mized in 3D simulations (Fig. S3, S4). The nomenclature of the sensors is 
derived from the subdivisions of the microfluidic channel: While the first 
cipher in the name specifies the number of channel sections (N), die 
second cipher enumerates the number of incubation areas within the 
respective channel section. The two incubation areas were separated by 
a 35-mm long spacer and differ in size to counteract unspecific reduction 
of the second signal peaks by lateral diffusion of the reporter molecule 
(H2O2). The number of electrochemical cells was reduced to only two: 
one for each channel section (i.e., two incubation areas). To assess its 
fluidic and mechanical characteristics as well as convenience of readout 
all incubation areas were functionalized with avidin-coupled GOx (1 μg 
ml− 1) for 1 h at room temperature. Subsequently, the substrate solution 
(glucose solution, 40 mM) was introduced to the channel and a 2-min 
stop flow protocol at a flow rate of 5 μl min− 1 was applied. 
The amperometric readout, shown in Fig. 3B displays four signal 
peaks (two for each electrochemical cell), which can be considered 
identically high as well as sufficiently separated when taking into ac-
count their respective baseline signals. In addition, the clean signal and 
neat alignment of the first two signal responses of each cell indicate 
properly working fluidics. As a consequence of the sequential arrange-
ment of the electrochemical cells, the last (in this case the second) cell in 
the row will measure an approximately two times higher baseline signal 
than the first one. This is, presumably, due to the accumulation of 
electroactive species within the respective incubation areas. Therefore, 
the signals detected by the first electrochemical cell (blue) are generally 
slightly lower than the ones measured by the second cell (orange), but 
this effect is mostly eliminated by subtraction of the baseline signals. 
The secondary peaks at 186 and 296 s (orange) can be attributed to the 
hydrogen peroxide from incubation areas non-correspondent to the 
second electrochemical cell, and therefore, neglected as unspecific. 
4.2. The 2x2x2N sensor 
Building onto the successful implementation of two serially arranged 
channel sections, the 2xN2 design was mirrored on the center line of the 
device to duplicate the total number of incubation areas (Fig. 4A). While 
the two separate microfluidic channels share a common inlet, each one 
has its own outlet, connected to individual syringe pumps, to increase 
fluidic control. Surface functionalization as well as measurement and 
readout were performed as described for the 2xN2 sensor. 
As for the 2xN2 chip version, the baselines recorded by the first 
electrochemical cells on either side of the chip were approximately half 
of what was recorded by the subsequent cells (Fig. 4B). However, after 
baseline subtraction, the signal peaks measured on the left side failed to 
reach their counterparts from the right. This phenomenon was repro-
ducibly observed for all tested 2x2xN2 sensors and could be due to the 
fact that the fluidic behavior of the channel on the right side is not ideal. 
An indication to strengthen this hypothesis is the substantial difference 
in the signal’s response to the stop of substrate flow at 18 s after mea-
surement onset: while there was a sharp drop in the signals measured by 
the cells on the left side (orange and blue), the signals measured on the 
right (red and black) only decreased slightly. As a result, there could be a 
slight but constant flow of substrate solution over the electrochemical 
cell, which makes the high signal peaks, measured on the right side, even 
more surprising. In addition, directly after restarting the flow, a small 
unspecific peak is measured by both electrochemical cells on the left side 
of the chip. These irregularities and deviations from the ideal fluidic 
behavior presumably originate in manufacturing imperfections of the 
channel walls, mechanical bending of the device or small flow varia-
tions, introduced by the syringe pump. Such signal behavior has not 
Fig. 3. (A) The 2xN2 sensor houses four incubation areas in two serially ar-
ranged channel sections. The incubation areas are functionalized with 1 μg 
ml− 1 of avidin-GOx and the 2-min stop-flow protocol is applied at a flow rate of 
5 μl min− 1. (B) Amperometric signal readout shows almost identical peaks for 
all incubation areas. (C) Tabular presentation of data collected from the first 
and second channel sections by their respective electrochemical cells (CS: 
channel section, BCSR: baseline corrected signal response, BL: baseline signal). 
Fig. 4. (A) The 2x2xN2 sensor houses eight incubation areas in four channel 
sections. The design was accomplished by mirroring the 2xN2 sensor on the 
central line. All incubation areas are functionalized with 1 μg ml− 1 of avidin- 
GOx and the 2-min stop-flow protocol is applied at a flow rate of 5 μl min− 1. 
(B) Amperometric signal readout shows slight shifts along the x-axis (time 
delay) between the signals as well as small artefacts due to fluidic problems. 
Also, the signals measured on the right side of the sensor are generally higher 
than the ones measured on the left. (C) Tabular presentation of data collected 
from the four channel sections by their respective electrochemical cells (CS: 
channel section, BCSR: baseline corrected signal response, BL: baseline signal). 
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been observed in the 2xN2 sensor, but in the 2x2xN2 version small 
imperfections might have an exaggerated impact on the uniformity of 
the flow. The design is, therefore, not used for further experiments, but 
might be a promising alternative, e.g., when implemented with stiffer 
channel materials. 
4.3. The 4xN2 sensor 
For the 4xN2 sensor chip, the 2xN2 is perpetuated serially to fill the 
entire chip format and form a single channel, housing a total of eight 
immobilization areas (Fig. 5A). The notation “4xN2” stems from the 
structure of the microfluidic channel, incorporating 4 distinct channel 
sections, each of which houses 2 incubation areas and one spacer. For 
the dimensions of incubation areas and spacers the same parameters that 
had already been employed in the 2x2xN2 chip were reused. Surface 
functionalization as well as measurement and readout were performed 
as described for the 2xN2 sensor. 
Interpretation of the results, however, was not trivial since the four- 
channel MultiEmStat3 potentiostat failed to record individual channels 
(i.e., electrochemical cells), although it is supposed to be able to record 
on all its channels simultaneously. However, the manufacturer also ac-
knowledges possible recording failures if all electrochemical cells are 
located in close proximity and immersed in the same electrolyte solu-
tion. In this case a sufficient galvanic separation of the channels would 
not be warranted. We consequently upgraded to a MultiEmStat3, which 
features a galvanic isolation module and is capable of recording up to 
eight channels in parallel without difficulties (Fig. 5B). While the 
amperometric readout does not display the anticipated distribution of 
baseline signals, the latter, as well as the recorded signal peaks, show 
fairly accurate alignment and similar heights. These values provide 
sufficient similarity to serve as proof-of-principle for the 4xN2 layout. 
Nevertheless, further measurements and possible tweaks in the stop- 
flow-protocol are required to develop the device’s performance to-
wards an ideal fluidic behavior. 
4.4. The 4xN1 sensor 
The layout of the 4xN1 sensor chip deviates from the previous ver-
sions in that it features no spacers, but each of the four incubation areas 
is directly followed by its own electrochemical cell, also acting as a 
spacer in itself (Fig. 6C). These alterations reduce fluidic problems 
originating from very long channel sections (e.g., by lowering the 
pressure drop) and facilitate interpretation of the readout. Additionally, 
the length of the incubation areas was extended to 22 mm for a more 
stable plateau behavior of the signal. Surface functionalization as well as 
measurement and readout were performed as described for the 2xN2 
sensor. 
These changes in the design of the multiplexed sensor were proven to 
be largely beneficial as all four principal signal peaks occur simulta-
neously and the alignment of the subsequent peaks indicates a properly 
working stop-flow-protocol without any undesirable flow variations 
inside the channel (Fig. 6A). As observed in previous chip versions, the 
hydrogen peroxide gradient that builds up along the length of the 
microfluidic channel is, again, visible in different levels of baseline 
signal recorded by the serially placed electrochemical cells. However, 
after subtraction of the baseline signals the, already fairly similar, 
principal peaks can be assumed to be identical. 
Given the almost ideal fluidic behavior of the 4xN1 design, we 
further used it for the simultaneous detection of miR-19b and miR-20a 
(Fig. 6B). To this end the channel was first pre-functionalized with 
streptavidin and then blocked with bovine serum albumin to prevent 
unspecific binding of biomolecules. Subsequently, the test solution, 
containing the effector protein (LwCas13a), the CRISPR-RNA (with the 
target-complementary guidance sequence), the target miRNAs (miR-19b 
or miR-20a) and the biotin- and 6-FAM-labelled reporter RNA, was 
applied to the channel inlets. The amperometric readout was performed 
as described for the 2xN2 sensor. To simulate the most difficult mea-
surement conditions we measured miR-19b (10 nM) in the fourth and 
miR-20a (10 nM) in the third incubation area, whereas the first and 
second incubation areas were tested with test solutions not containing 
Fig. 5. (A) For the 4xN2 sensor, the 2xN2 chip design is serially perpetuated to 
a total of eight incubation areas. These (two per channel section) are func-
tionalized with 1 μg ml− 1 of avidin-GOx and the 2-min stop-flow protocol is 
applied at a flow rate of 5 μl min− 1. (B) Amperometric readout reveals close 
alignment of all primary and secondary signal responses as well as baseline 
signals. (C) Tabular presentation of data collected from the four channel sec-
tions by their respective electrochemical cells (CS: channel section, BCSR: 
baseline corrected signal response, BL: baseline signal). 
Fig. 6. (A) The incubation areas of the 4xN1 sensor are functionalized with 1 
μg ml− 1 of avidin-GOx and the 2-min stop-flow protocol is applied at a flow rate 
of 5 μl min− 1 to validate the basic design concept. Signal readout shows 
simultaneous and almost identical signal peaks for the one-step assay. (B) 
Multiplexed miRNA measurement of 10 nM of miR-19b in the 4th and miR-20a 
in the 3rd immobilization area (blue and orange) and without target (first and 
second immobilization area; red and black) shows a signal drop of 94.88% for 
10 nM of target RNA. (C) In the 4xN1 chip design, each channel section houses 
one incubation area and instead of spacers, each of these is followed by its own 
electrochemical cell (CS: channel section, BCSR: baseline corrected signal 
response, BL: baseline signal). (For interpretation of the references to colour in 
this figure legend, the reader is referred to the Web version of this article.) 
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the targets: elevated baseline levels lead to a decrease in dynamic range 
and could affect the limit of detection by compression of the standard 
curve. Using this particular sequence, the first two incubation areas 
produced 264.14 μA cm-2 and 246.59 μA cm-2 (baseline subtracted) 
peaks, leading to substantial baseline levels that were subsequently also 
measured by the 3rd and 4th cell, which did not produce any signals 
(12.21 μA cm-2 and 13.94 μA cm-2; baseline subtracted). The samples 
containing the targets provide proof-of-concept for the CRISPR-powered 
methodology we used for nucleic acid detection, as the reporter RNA 
was completely cleaved by the successfully activated effector protein. 
5. Conclusions 
In this study, we successfully validate our CRISPR-powered assay in 
the simultaneous, spatially separated detection of multiple nucleic acids 
in a single microfluidic channel using the CRISPR-Biosensor X. The 
combination of a single channel LOC device for the analysis of up to 
eight analytes with the stop-flow-protocol has the potential to overcome 
many technical, like simplicity and sensitivity, and non-technical like 
costs and acceptance in clinical practice, barriers for multiplexing and 
thus, to make a great impact on point-of-care diagnostics (for example, 
hospitals or other settings without well-equipped central laboratories). 
The arguably biggest advantage that our bioassay has to offer in 
terms of multiplexing capabilities is the flexibility to target various 
RNAs of interest from a single clinical sample using only one effector 
protein and without changing the sensor or measurement setup. In order 
to change the analyte, the only component that needs adjustment is the 
target complementary sequence of the CRISPR RNA. Extension of the 
existing system for the sake of multiplexing, of course, gives rise to new 
challenges, like possible cross-reactivity by diffusion between the 
different incubation areas or increasingly complex chip-fabrication, 
assay preparation and amperometric readout. We will therefore 
further focus on optimization of the chip fabrication, development of a 
standardized readout interpretation and the clinical validation of the 
CRISPR-Biosensor X. 
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